ARWR
Arrowhead Pharmaceuticals Inc
71.90$
+4.5%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -20,237.9% | -17,200.9% | -40,691.1% | -76.2% | -292.5% | 102.5% | -108.9% | 123.9% | -56.0% | -63.9% | -13,034.4% | 21.6% | |
| 768.9% | 611.6% | 2,059.0% | 14.9% | 29.1% | 2.6% | 6.8% | 6.0% | 4.3% | 5.2% | 523.7% | 2.9% | |
| 3,255.0% | 2,678.8% | 7,323.7% | 25.1% | 52.4% | 7.3% | 49.3% | 55.4% | 49.7% | 32.5% | 2,083.0% | 7.6% | |
| 8,045.5% | 5,073.0% | 5,106.4% | 22.3% | 49.7% | 8.0% | 49.3% | 55.4% | 51.5% | 37.6% | – | – | |
| 2,859.8% | 892.1% | 3,611.6% | -3.8% | -36.4% | 51.6% | -69.4% | 165.4% | -40.4% | -21.4% | 706.6% | -2.2% | |
| 981.3% | 515.9% | 2,438.0% | 25.2% | 8.8% | 7.1% | 13.6% | 17.0% | 21.7% | 73.4% | 3,983.9% | 2.7% | |
| -20,846.7% | 3,696.6% | 8,493.3% | -154.9% | -46.1% | -28.3% | -273.6% | -102.5% | -2.2% | -39.9% | -11,829.7% | -15.6% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 106,011.3% | 132.1% | -400.5% | -1.4% | -0.3% | 40.8% | 293.1% | 8.2% | 2.1% | – | – | – | |
| -128.8% | -56.0% | -137.4% | -0.6% | -1.3% | -1.4% | 284.1% | 180.8% | 102.8% | 103.8% | 11,039.1% | -23.1% | |
| 105,882.5% | 76.1% | 34,820.2% | 38.4% | 371.4% | 39.3% | 293.1% | 8.2% | 26.8% | 105.1% | 24,514.8% | 8.9% | |
| 64,797.8% | -13,428.3% | 2,622.4% | -192.7% | 32.8% | 113.6% | -88.9% | 29.5% | -31.4% | 1.2% | -231.1% | 14.9% | |
| -21,219.3% | -17,716.8% | -43,129.2% | -101.4% | -301.3% | 95.4% | -122.5% | 106.8% | -77.7% | -137.3% | -17,018.3% | 18.9% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.